tbuckley/cabot-search huggingface dataset:
RTHP-01. COMPARISON OF CO-PLANAR AND NON-COPLANAR TREATMENT PLANNING FOR TUMOR NEARBY CRITICAL ORGANS IN HIGH GRADE GLIOMAS
Authors: Hande Ba, ş Ayata, Cemile Ceylan
Journal: Neuro-Oncology (2016)

The goal of this study was to compare six treatment planning methods (IMRTand VMAT) for high grade gliomas that had PTVs overlapping the optic pathway and/or brainstem. METHOD AND MATERIALS:27 previously treated patients were replanned with IMRT5,IMRT7,IMRT7-non, VMAT2f, VMAT2hand VMAT2h-non.For this comparison study, it was selected in three different localization (right, left and center sided tumors) of the tumor. PTVoptics and PTVbrainstem was limited to a maximum dose limit equal to 54Gy and minimum dose limit of 51Gy. A comparison of the three IMRT plans with three VMAT plans were performed in all 27 patients. The mean dose of the PTV was 60.16 ± 46.84 in IMRT5, 60.31 ± 47.48 in IMRT7, 60.30 ± 51.64 in IMRT7-non, 60.22 ± 55.32 in VMAT2f, 60.18 ± 94.51 in VMAT2h and 60.36 ± 84.11 in VMAT2h-non.The mean CI was significantly higher with the all IMRT plans, compared to all VMAT plans (p<0.05 for all comparisons) in left and right sided tumors. There was also significant differences between coplanar and non-coplanar plans in IMRT and VMAT plans in right sided tumors (p<0.05). IMRT5,IMRT7,IMRT7-non,VMAT2f,VMAT2h and VMAT2h-non resulted in mean doses to brainstem of 23.79Gy, 23.6Gy, 24.77Gy, 23.43Gy, 24.64Gy and 24.23Gy, respectively. Only in center sided tumors, there were significant differences between coplanar and noncoplanar plans in brainstem mean doses(IMRT5-IMRT7-nonp=0.00849, IMRT7-IMRT7-nonp=0.011, IMRT5-VMAT2h-nonp=0.0153 and VMAT2f-VMAT2h-nonp=0.0166). Radiation doses to the ipsilateral optic nerves mean, ipsilateral lens mean, ipsilateral retina mean and maximum, contralateral optic nerves mean and maximum, contralateral retina mean, contralateral lens mean and maximum and optic chiasm maximum were higher with the VMAT2f plans than with the all of IMRT plans (IMRT5,IMRT7 and IMRT7-non) in the right and left sided tumors. While VMAT2f plans had a significantly longer delivery time than VMAT2h and VMAT2h-non (p=0.0003), the absolute difference in the mean treatment time was not so large. IMRT techniques provided better target coverage than VMAT plans. VMAT techniques reduced treatment delivery time compared to IMRT techniques.
Overxpression of HER2/neu in uterine carcinosarcoma
Authors: T. Nishikawa, K. Yonemori, H. Okuma, A. Kawachi, A. Kitano, T. Shimoi, A. Shimomura, E. Noguchi, M. Yunokawa, H. Yoshida, C. Shimizu, Y. Fujiwara, K. Tamura
Journal: Annals of Oncology (2016)
Reply to Salvador Vale's Letter to the Editor re: Cesare Cozzarini. Whole-pelvis Radiotherapy in the Radiation Treatment of Intermediate- and High-risk Prostate Cancer: How to Improve the Therapeutic Ratio of a Potentially Effective but still Unsatisfactory Treatment? Eur Urol 2017;71:44–5. Preclinical Combinatory Approach to Enhance Radiotherapy Effects and Reduce its Morbidity may be Tested in the Clinic
Authors: Cesare Cozzarini, Fabio Benigni, Claudio Fiorino, Anna Mondino, Nadia Di Muzio
Journal: European Urology (2017)
Clinicians identify high need to increase their genomic literacy to applied cancer genomics
Authors: J. Laskin, D. Ha, T. Chan, A. Fok, K.A. Gelmon, A. Charters, R. Yoshizawa, S. Struve, C. Ho, D. Renouf, H. Lim, C. Simmons, S. Taylor, A. Tinker, J.-P. McGhie, S. Jones, M. Marra, P. Chow-White
Journal: Annals of Oncology (2016)
Nivolumab monotherapy in metastatic urothelial cancer (mUC): Updated efficacy by subgroups and safety results from the CheckMate 032 study
Authors: J.E. Rosenberg, P. Bono, J. Kim, P. Spiliopoulou, E. Calvo, R. Pillai, P.A. Ott, F. de Braud, M. Morse, D. Le, D. Jaeger, E. Chan, C. Harbison, C.S. Lin, M. Tschaika, A. Azrilevich, P. Sharma
Journal: Annals of Oncology (2016)
Overexpansion of Th17 and Th1/17 Cells in Patients with Myelodysplastic Syndrome
Authors: Elena E. Solomou, A. Tsanaktsi, V. Fertakis, K. Dallas, S. Karambina, M. Tiniakou, A. Kourakli, I. Micheva, A. P Andonopoulos, S.N C Liossis, P. Matsouka, Nicholas Zoumbos
Journal: Blood (2008)
Elderly Patients with Early-Unfavorable Stage Hodgkin’s Disease (HD) Have a Poorer Outcome When Treated with Combined Modality Treatment and Extended Field Radiotherapy (EF): A Retrospective Analysis of the German Hodgkin Study Group.
Authors: Andreas Engert, Heinz Haverkamp, Hans T. Eich, Andreas Josting, Beate Pfistner, Volker Diehl
Journal: Blood (2004)
Flow Cytometry Thresholds of Myeloperoxidase Detection to Discriminate Between Acute Lymphoblastic or Myeloblastic Leukemia
Authors: Julien Guy, Iléana Antony-Debré, Isabelle Arnoux, Chantal Fossat, Emmanuel Benayoun, Magali Le Garff-Tavernier, Anna Raimbault, Michèle Imbert, Marc Maynadie, Francis Lacombe, Marie C Béné, Orianne Wagner-Ballon
Journal: Blood (2012)
Use of lipegfilgrastim in clinical practice for the prophylaxis of chemotherapy-induced neutropenia: interim results of pan-European non-interventional study
Authors: P. Pichler, N. Claes, P. Mazza, B. Zurawski, P. Potocki, E. Petru, M. Šedivá, J. Katolicka, F. Lanza, C. Fontaine
Journal: Annals of Oncology (2016)
Laser lithotripsy resolution for Bouveret syndrome
Authors: Cristina Saldaña Dueñas, Ignacio Fernández-Urien, María Rullán Iriarte, Juan Vila Costa
Journal: Endoscopy (2017)

A 75-year-old woman was admitted with epigastric pain, nausea, and vomiting, but without any other symptoms. Laboratory testing and physical examination were normal. Her abdominal computed tomography (CT) scan on admission identified a cholecystoenteric fistula (duodenum to distal antrum) with a 4-cm stone in the duodenum, all of which was compatible with Bouveret syndrome ([Fig. 1]) We performed a gastroscopy, which identified pyloric obstruction due to a huge stone that was preventing advancement of the endoscope ([Fig. 2 a]). The patient was discussed with the surgical department, following which conservative management involving endoscopic removal was chosen.
Detection of EGFR mutations in tissue and plasma of NSCLC Patients
Authors: M.G. Bica, C. Russo Lacerna, F. Guddo, M. Spatafora, S. Cannella, F. Spinnato, G. Agneta, A. Rizzo, F. Verderame, A. Santoro
Journal: Annals of Oncology (2016)
Constitutive Activation of FLT3 Is a Positive Prognostic Factor in Infants with MLL-Rearranged Acute Lymphoblastic Leukemia
Authors: Henning Fedders, Denis Martin Schewe, Martin Zimmermann, Ameera Alsadeq, Anja Moericke, Udo zur Stadt, Martin A. Horstmann, Rob Pieters, Martin Schrappe, Gunnar Cario, Martin Stanulla
Journal: Blood (2015)
Feasibility of Hematopoietic Stem Cell Collection and Cryopreservation in Waldenstrom's Macroglobulinemia
Authors: Dilshad Khan, Krina Patel, Sheeba K. Thomas, Donna M. Weber, Kay B Delasalle, Chitra M. Hosing, Uday R. Popat, Qaiser Bashir, Nina Shah, Simrit Parmar, Richard E. Champlin, Muzaffar Qazilbash
Journal: Blood (2012)
Patients Mobilizing Large Numbers of CD34+ Cells ("Super-Mobilizers") Have Improved Survival in Autologous Stem Cell Transplantation for Lymphoid Malignancies.
Authors: Brian J. Bolwell, Brad Pohlman, Lisa Rybicki, Matt Kalaycio, Ronald Sobecks, Robert M. Dean, Laura Bernhard, Kelly Cherni, Christina Ferraro, Jenny Bates, Stacey Brown, John William Sweetenham
Journal: Blood (2006)
NIMG-51. IMPACT ON REMOTE FUNCTIONAL AREAS DUE TO TUMOR MASS EFFECT IS PROGNOSTIC OF OVERALL SURVIVAL IN GLIOBLASTOMA MULTIFORME
Authors: Jhimli Mitra, Ameya Nayate, Anant Madabhushi, Pallavi Tiwari
Journal: Neuro-Oncology (2016)

Neurological deficits and seizures due to intra-cranial pressure (ICP) exerted from the growing tumor and associated mass effect are one of the first clinical symptoms in Glioblastoma Multiforme (GBM). However, little is known about the specific functional areas that are impacted due to increased ICP within the confined cranial vault, and the role of this impact in overall patient outcome. In this work, we hypothesized that deformation due to tumor mass effect in eloquent and functional areas of the brain perhaps leads to increased neurological deficits, resulting in poor patient outcome. We measured the deformation in remote brain areas due to GBM mass effect based on the laterality of the primary tumors on a total of 89 GBM subjects (48 left-sided tumors, 41 right-sided tumors) from T1w MRI. The T1w MRI images were non-rigidly registered to a normal atlas to measure the tissue deformations surrounding the tumor. The distribution of deformation within each of the functionally eloquent areas of the brain was correlated with the length of overall survival (mean: 469.83 ± 397.31 days). Survival (mean: 469.83 ± 397.31 days) time was highly associated (R>-0.40, p<0.05) with the deformation in both left and right temporal gyri, post-central gyri, olfactory and insular cortices and right supra-marginal gyrus, for the tumors of the right hemisphere. As mass effect can deform regions in contra-lesional hemisphere, the negative impact of deformation on survival was therefore observed across both hemispheres in areas known for language comprehension, social cognition, visual perception, and emotion, somato-sensory, cognitive and motor-control functions. The study findings suggest that the increased deformation in remote functional areas due to mass effect was correlated with decreased overall survival perhaps due to neurological deficits. Once validated on a larger cohort, these findings could provide insights into the palliative therapy and management of GBM patients.
Quality of life in patients with metastatic colorectal cancer receiving maintenance therapy after first-line inductive treatment: A quality of life sub-analysis of the AIO KRK 0207 phase III trial
Authors: J. Quidde, S. Hegewisch Becker, U. Graeven, C. Lerchenmueller, B. Killing, R. Depenbusch, C.-C. Steffens, T. Lange, G. Dietrich, J. Stoehlmacher, A. Reinacher, A. Tannapfel, T. Trarbach, N. Marschner, H.J. Schmoll, A. Hinke, S.-E. Al-Batran, D. Arnold
Journal: Annals of Oncology (2016)
RARE-60. ATYPICAL RHABDOID TERATOID TUMOR: A CASE IN PREGNANCY AND ANALYSIS OF ADULT CASES TO DATE
Authors: Chris Dardis, Kelly Milton
Journal: Neuro-Oncology (2016)

Atypical rhabdoid teratoid tumors (ATRT) classically develop in infancy and are rare in adults. We present the 48th case to date, the third such during pregnancy. The disease tends to follow a biphasic course i.e. if growth is not arrested following the first relapse/ progression, death is almost universal. While typically rapidly fatal, as in our case, long-term remission appears possible. Uni-variable Cox proportional-hazards models of adult cases showed significantly worse survival with: glial differentiation (HR 7.3, p<0.01), leptomeningeal dissemination (HR 4.3, p<0.01) - these were highly correlated (chi-squared <0.01) and pregnancy (HR 3.9, p=0.09). The finding that glial differentiation worsens outcomes is novel. Improved survival was seen with extent of resection (ordinal scale; p<0.01 for model) and use of craniospinal irradiation (CSI; HR 0.2, p=0.07). Systemic chemotherapy was of marginal significance (HR=0.5, p=0.13). Use of intrathecal chemotherapy was too rare to draw any conclusions. 22/46 cases originated in midline structures next to CSF, thus leading to a high rate of leptomeningeal dissemination. All 10 cases in the pituitary were in females. 3/6 cases in those aged >50 began in/beside the spinal cord. We hypothesise that the cicumventricular organs, particularly the pituitaty and pineal glands are the most common origin of these tumors. There appears to be a pool of cells dividing in the above organs, rapidly in infancy and slowly throughout much of adulthood. Review of immunohistochemistry shows ectodermal elements, with epidermal-to-mesnchymal transition; thus ATRT may be a misnomer. Loss of INI1 is neither necessary not sufficient to account for ATRT. We suggest that the development of ATRT requires an epigenetic change. Treatment options in adults differ from infants in that CSI is a viable adjunct to chemotherapy. Myelotoxicity is a concern with multimodality treatment. We suggest that facilities for peripheral blood stem-cell transplant be available.
MPTH-26. CXCL13 AND IL-10 IN CEREBROSPINAL FLUID (CSF) AS AN IMPORTANT BIOMARKER FOR PRIMARY CENTRAL NERVOUS SYSTEM CELL LYMPHOMA (PCNSL)
Authors: Takashi Sasayama, Kazuhiro Tanaka, Masamitsu Nishihara, Hiroaki Nagashima, Katsu Mizukawa, Junichi Sakata, Masahiro Maeyama, Eiji Kohmura
Journal: Neuro-Oncology (2016)

Malignant lymphoma cells are known to secrete various cytokines and chemokines. We previously reported that the cerebrospinal fluid (CSF) level of interleukin-10 (IL-10) was useful biomarker for primary central nervous system lymphomas (PCNSLs). Recently, CXC chemokine ligand 13 (CXCL13) level in CSF was also reported to be useful biomarker for PCNSL. We analyzed CSF CXCL13 levels in the patients with various brain diseases, including PCNSLs, and compared with other biomarkers for PCNSLs. One hundred fourteen CSF samples were analyzed. Thirty samples were PCNSL (all diffuse larger B-cell lymphomas) and 84 samples were other brain diseases (brain tumors and inflammation diseases, etc). The CXCL13 levels were measured by ELISA. In addition, IL-10, IL-6, sIL-2 receptor, b2-microglobulin in CSF were measured and compared with CXCL13. Also, relationship between CXCL13 levels and prognosis (overall survival (OS) and progression-free survival (PFS)) was analyzed by Cox proportional hazards model. Mean CXCL13 concentrations in CSF were 1117.6 pg/ml (114.7~1934.7 pg/ml) and 29.1 pg/ml (0.3~345.1 pg/ml) in PCNSLs and other brain diseases, respectively. CXCL13 levels in CSF were significantly increased in PCNSLs compared with other brain diseases (p<0.0001). CSF CXCL13 levels had higher discrimination power of PCNSL (AUC=0.99) than CSF IL-10 (AUC=0.96), sIL-2 receptor (AUC=0.86), and b2-microglobulin (AUC=0.94). Also, diagnostic accuracy was improved by bivariate evaluation of CSF IL-10 and CXCL13. Furthermore, CXCL13 levels in CSF were statistically associated with OS (HR=1.001, 95% CI 1.000~1.002, p=0.03) and PFS (HR=1.001, 95% CI:1.000~1.002, p=0.02) in the patients with PCNSL. These results indicate that the CSF CXCL13 levels were quite useful diagnostic biomarker for the patients with PCNSLs. The measurement of both CXCL13 and IL-10 concentration in CSF could improve the diagnostic accuracy for PCNSLs. In addition, CSF CXCL13 may be a prognostic marker for PCNSL.
HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and T-DM1
Authors: J. Cortes Castan, S. Verma, S. Hurvitz, I.E. Krop, D. Tripathy, D.A. Yardley, M. Dionne, J. Reynolds, T. Wickham, I. Molnar, K. Miller
Journal: Annals of Oncology (2016)
Italian cohort of nivolumab Expanded Access Programme (EAP): efficacy and safety data from a real-world population
Authors: L. Crinò, P. Bidoli, A. Delmonte, F. Grossi, F. de Marinis, F. Sperandi, F. Piantedosi, M. Vitali, H. Soto Parra, S. Scagnoli, G. Minuti, L. Calabrò, M. Tiseo, D. Turci, S. Quadrini, P. Antonelli, A. Manzo, I. Prediletto, D. Giannarelli, D. Galetta
Journal: Annals of Oncology (2016)
Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Authors: Constantine S. Tam, Stephen Opat, Gavin Cull, Judith Trotman, David Gottlieb, David Simpson, Paula Marlton, Mary Ann Anderson, Matthew Ku, David Ritchie, Sumita Ratnasingam, Bradley Augustson, Mark Kirschbaum, Lai Wang, Ling Xue, Jianxin Yang, Eric Hedrick, John F Seymour, Andrew W. Roberts
Journal: Blood (2016)
PDTB-04. CASEIN KINASE 2 REGULATES EXPRESSION AND ACTIVITY OF MYC IN GROUP 3 MEDULLOBLASTOMA
Authors: Benjamin Jin, Ryan Nitta, Gordon Li
Journal: Neuro-Oncology (2016)

Medulloblastomas are a malignant (WHO grade IV) brain tumor that comprise the majority of pediatric brain tumors. They are classified into four molecular subgroups each highlighted by amplification of a certain oncogene. The group 3 medulloblastoma subgroup is characterized by MYC amplification and has the worst prognosis. A novel therapeutic target for medulloblastomas is casein kinase 2 (CK2), a tetrameric enzyme composed of two catalytic alpha (CK2α) and two regulatory beta (CK2β) components. CK2 is noted to be overexpressed plays an important role in the development of several cancers. Our preliminary findings demonstrate that medulloblastoma patients with enhanced CK2α expression have a worse prognosis indicating that CK2 may play an important role in this disease. Further research showed that CK2 regulates medulloblastoma tumorigenesis through the regulation of the proto-oncogene, c-Myc. We stably transduced the D425 medulloblastoma cell line with either exogenous CK2α or CK2β and discovered that enhanced expression of CK2α or CK2β increased the expression and transcriptional activity of c-Myc when compared to that of an YFP-expressing control cell line. We additionally discovered that inhibition of CK2 by the small molecule inhibitor, CX-4945, decreased c-Myc expression in a dose-dependent manner. Knockout of CK2α or CK2β utilizing a CRISPR/Cas9 system also resulted in a decrease in c-Myc expression and transcriptional activity. Lastly, cell lines with enhanced CK2 expression were shown to have increased cellular proliferation and anchorage-independent growth, while inhibition or knockdown of CK2α or CK2β decreased medulloblastoma growth. We verified that CK2 regulates medulloblastoma tumorigenesis through c-Myc by knocking down c-Myc expression in the exogenous CK2-overexpression cell lines, which then demonstrated a decrease in tumorigenic potential. Overall, our study indicates that CK2 is an important regulator of Myc expression and can alter medulloblastoma tumorigenesis through Myc-related pathways.
Possible Relation of Crohn’s Disease and Hereditary Thrombophilia: Detection of ASCA Seropositivity. (Preliminary Results).
Authors: Georgia Lazaraki, Fotios Girtovitis, Stefanos Dokas, Eleftheria Pithara, Maria Tsaousidou, Aikaterini Spartali, Pantelis Makris
Journal: Blood (2004)
A phase 1 study evaluating the pharmacokinetics (PK) and safety of regorafenib (REG) in patients with advanced solid tumors with severe renal impairment (SRI)
Authors: D.J. Renouf, H.W. Hirte, C.L. O'Bryant, Z.J. Trnkova, A. Cleton, F. Huang, U. Mueller, J.-P. Ayoub, A.C. Lockhart, D.I. Quinn, G.K. Dy, M.B. Sawyer
Journal: Annals of Oncology (2016)
IMST-57. THERAPEUTIC POTENTIAL OF THE NATURAL HUMAN IgG1k ANTIBODY PRITUMUMAB
Authors: Ivan Babic, Rajesh Mukthavaram, Phenix Jiang, Natsuko Nomura, Sandeep Pingle, Mark Glassy, Santosh Kesari
Journal: Neuro-Oncology (2016)

Pritumumab is a natural human IgG1 kappa antibody derived from a regional draining lymph node of a patient with cervical carcinoma. The recognized antigen is an altered form of vimentin, called ecto-domain vimentin (EDV), expressed on the cell surface of epithelial tumor cells. A recombinant version of the mAb was made using the GPEx® system in CHO cells. In a series of comparable studies the CHO mAb was compared with the original hybridoma. Binding specificity with both flow cytometry and immunohistochemical analysis, Western blot analysis, and Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) activity confirms the comparability of the two versions. Studies include establishing a xenograft model with both SCID and athymic nude mice in which pritumumab was effective in preventing tumor growth in nude mice but not in SCID mice. Analysis of a blood brain barrier model suggests pritumumab shows minimal distribution in normal brain tissues and significant binding in tumor areas of brain tissues indicating the mAb crosses the tumor brain barrier. Overall, these data together suggest pritumumab is suitable for development as an anti-tumor therapeutic.
Comparison of Patient Report and Medical Records of Comorbidities
Authors: Fan Ye, Dominic H. Moon, William R. Carpenter, Bryce B. Reeve, Deborah S. Usinger, Rebecca L. Green, Kiayni Spearman, Nathan C. Sheets, Kevin A. Pearlstein, Angela R. Lucero, Mark R. Waddle, Paul A. Godley, Ronald C. Chen
Journal: JAMA Oncology (2017)

<h3>Importance</h3> The comorbid conditions of patients with cancer affect treatment decisions, which in turn affect survival and health-related quality-of-life outcomes. Comparative effectiveness research studies must account for these conditions via medical record abstraction or patient report. <h3>Objective</h3> To examine the agreement between medical records and patient reports in assessing comorbidities. <h3>Design, Setting, and Participants</h3> Patient-reported information and medical records were prospectively collected as part of the North Carolina Prostate Cancer Comparative Effectiveness &amp; Survivorship Study, a population-based cohort of 881 patients with newly diagnosed localized prostate cancer enrolled in the North Carolina Central Cancer Registry from January 1, 2011, through June 30, 2013. The presence or absence of 20 medical conditions was compared based on patient report vs abstraction of medical records. <h3>Main Outcomes and Measures</h3> Agreement between patient reports and medical records for each condition was assessed using the κ statistic. Subgroup analyses examined differences in κ statistics based on age, race, marital status, educational level, and income. Logistic regression models for each condition examined factors associated with higher agreement. <h3>Results</h3> A total of 881 patients participated in the study (median age, 65 years; age range, 41-80 years; 633 white [71.9%]). In 16 of 20 conditions, there was agreement between patient reports and medical records for more than 90% of patients; agreement was lowest for hyperlipidemia (68%; κ = 0.36) and arthritis (66%; κ = 0.14). On multivariable analysis, older age (≥70 years old) was significantly associated with lower agreement for myocardial infarction (odds ratio [OR], 0.31; 95% CI, 0.12-0.80), cerebrovascular disease (OR, 0.10; 95% CI, 0.01-0.78), coronary artery disease (OR, 0.37; 95% CI, 0.20-0.67), arrhythmia (OR, 0.44; 95% CI, 0.25-0.79), and kidney disease (OR, 0.18; 95% CI, 0.06-0.52). Race and educational level were not significantly associated with κ in 18 of 19 modeled conditions. <h3>Conclusions and Relevance</h3> Overall, patient reporting provides information similar to medical record abstraction without significant differences by patient race or educational level. Use of patient reports, which are less costly than medical record audits, is a reasonable approach for observational comparative effectiveness research.
Internal tandem duplications in FLT3 detected by anchored multiplex PCR and next-generation sequencing
Authors: B. van Deusen, M. Bessette, L. Johnson, A. Berlin, M. Banos, L. Griffin, E. Reckase, J. Stahl, A. Licon, J.W. Myers, B. Kudlow
Journal: Annals of Oncology (2016)
Screening does not reduce mental disorders in returning soldiers, study finds
Authors: Nigel Hawkes
Journal: BMJ (2017)

Screening soldiers for mental disorders after they return from battle is a waste of money, a large randomised controlled trial (RCT) has shown.1

The results of the £2m (€2.34m; $2.5m) study, funded by US taxpayers and carried out in the UK at King’s College Centre for Military Health Research, London, cast doubt on mental health screening programmes for armed service personnel introduced by several countries, including the US.

The study was possible because the UK—unlike the US, Australia, Canada, and the Netherlands—has never introduced such a programme. Once screening is introduced, RCTs cannot be conducted, Simon Wessely of King’s College told a briefing at London’s Science Media Centre, because it is then impossible to create a control group by randomly allocating some participants to having no screening.

“Once …